Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Science of Chronic Itch

Shivani V. Tripathi, MD, & Brian S. Kim, MD, MTR  |  Issue: December 2014  |  December 1, 2014

Collectively, these emerging studies demonstrate that the factors and pathways regulating itch are much more heterogeneous than previously recognized (see Figure 1). This new scientific paradigm of itch biology may help us to better understand and conceptualize the different forms of itch and their potential treatments.

Emerging studies demonstrate that the factors & pathways regulating itch are much more heterogeneous than previously recognized.

Categories of Itch

Acute itch, as seen in response to arthropod bites and poison ivy, is transient in nature. In contrast, chronic itch is highly debilitating and its etiology is often difficult to define. Chronic itch, defined as lasting greater than six weeks, accompanies a number of inflammatory skin diseases, such as AD and psoriasis, as well as systemic conditions, such as CKD and cholestasis.14 The presentation of chronic itch can be divided into five different clinical categories to help organize the clinical approach, diagnosis and treatment:15

  1. Systemic itch;
  2. Neuropathic itch;
  3. Psychogenic itch;
  4. Idiopathic itch; and
  5. Dermatologic itch.

In this review, we briefly outline our current understanding of each category of chronic itch and its potential treatments. Further, we highlight chronic pruritus as a problem in the context of rheumatologic and autoimmune diseases. Although the five categories of chronic itch overlap at times in terms of their pathophysiology and treatments, this structure allows for a systematic and logical clinical approach (see Table 1).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Systemic Itch

The causes of systemic itch are broad and include renal failure, cholestasis and other related hepatic diseases, malignancies, endocrine disorders, systemic infection and exposure to specific drugs. Although a variety of medical conditions underlie chronic itch due to systemic causes, a common theme among these disorders is that a systemic factor is either overproduced or inadequately metabolized and excreted to mediate the itch response. In the following section, we highlight current concepts and treatments regarding a few forms of the most common causes of systemic itch.

CKD is one of the main causes of systemic itch and is often referred to as renal pruritus. Renal pruritus affects up to 58% of patients with renal failure.16 It can be either intermittent or constant and most commonly affects the back, in addition to the head, arms and abdomen.17 Although the pathophysiology is unknown, multiple hypotheses have been suggested. For example, it has been proposed that immune dysregulation underlies renal pruritus, based on the observation that patients respond to immunosuppressive light therapy.18

Beyond the immune system, the accumulation of calcium, magnesium and phosphate due to a lack of renal clearance has also been hypothesized as a contributor. In support of this, symptoms often improve following interventions that normalize electrolytes, such as parathyroidectomy.19

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:ConditionsEducation & TrainingMyositisProfessional TopicsResearch Rheum Tagged with:chronic pruritusitchKimmyositispathophysiologypatient careResearchrheumatology

Related Articles

    Psoriasis May Itch as Intensely as Atopic Dermatitis

    June 13, 2017

    NEW YORK (Reuters Health)—Itch intensity in moderate to severe plaque psoriasis can be substantial, and may be on a par with the notoriously itchy skin condition atopic dermatitis, new research suggests. “Both conventional wisdom and some of our classic dermatologic textbooks have stated that psoriasis is not particularly itchy,” corresponding author Dr. Alexa B. Kimball…

    How to Manage Pain in Patients with Renal Insufficiency or End-Stage Renal Disease on Dialysis

    October 1, 2013

    Narcotic and non-narcotic pain regimens can be used

    Lost and found

    The History of ACE Inhibitors in Scleroderma Renal Crisis

    February 16, 2021

    Scleroderma renal crisis is a true medical emergency in rheumatology, one that requires prompt diagnosis and treatment. Here, we review the historic introduction of the angiotensin-converting enzyme inhibitors in this context, and highlight management and key questions moving forward. Background Awareness of renal disease in scleroderma dates back many years. The revered physician William Osler…

    MicroOne / shutterstock.com

    Rheumatology Drugs at a Glance, Part 2: Psoriasis

    May 17, 2019

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences